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Many factors contribute to the development of atherosclerosis. 
Over the past few years, understanding of the importance of 
inflammation during all stages of atherosclerosis, including its 
initiation through the progression and the complication of 
thrombosis, has increased greatly. Under normal conditions, 
the vessel wall has its own machinery to maintain vascular ho-
meostasis. However, the balance is broken when repetitive met-
abolic stimuli resulting from hypertension, insulin resistance 
or obesity strike the vessel wall. Most of these metabolic stim-
uli disturb homeostasis through the initiation of inflammation, 
that is the recruitment of inflammatory cells, the increased ad-
hesion molecules, secretion of chemoattractant and proinflam-
matory cytokines from the endothelial cells and the migration 
and proliferation of smooth muscle cells from media [1]. Among 
the top contributors of inflammatory stimuli are adipokines 
secreted from adipose tissue, which is now considered not as a 
mere mass of fat tissue, but an active organ that acts as a reser-
voir for energy in the energy excess state and as an active sup-
plier of energy when the body runs short of it. Adipokines have 
diverse autocrine, paracrine and endocrine actions and have 
been implicated in the pathogenesis of metabolic syndrome 
and cardiovascular disease. 
  Chemerin, also known as tazarotene-induced gene 2 protein 
(TIG2) or retinoid acid receptor responder 2 (RARRES2), was 
a recently identified novel adipokine that has a role in adaptive 
and innate immunity [2]. Chemerin acts as a secreted ligand 
of the orphan G protein-coupled receptor chemokine-like re-
ceptor (CMKLR) 1, chemokine (C-C motif) receptor-like 
(CCRL) 2 and the G protein-coupled receptor (GPR) 1. Vari-
ous cell types involved in innate and adaptive immunity ex-
press CMKLR1, and chemerin is known to function as a che-
moattractant that promotes recruitment of immune cells to 
sites of injury [3,4]. Chemerin is translated as a pre-protein 
that is secreted as a proprotein following the proteolytic cleav-
age of a signal peptide [3,5]. This proprotein has low biological 
activity, and requires further C-terminal processing by plas-
min, carboxypeptidases or serine protease of the coagulation, 
fibrinolytic and inflammatory cascades. This processing is sug-
gested to be the key regulatory mechanism that affects the con-
centration of bioactive chemerin.
  Increased chemerin expression in adipocytes was demon-
strated in mice fed a high fat diet [6]. Chemerin is known to 
be induced during adipocyte differentiation and increases in-
sulin-stimulated glucose uptake in adipocytes [7]. A recent 
study suggested that overexpression of human chemerin in 
low-density lipoprotein receptor knockout (LDLRKO) mice 
induced insulin resistance in skeletal muscle and administra-
tion of chemerin exacerbated glucose intolerance, lowered in-
sulin levels, and decreased tissue glucose uptake in obese/dia-
betic mice [8]. In addition, chemerin is shown to be expressed 
differentially according to different fat depots [9]. In human 
studies, chemerin levels correlated with metabolic factors re-
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lated to obesity, such as body mass index, triglyceride levels 
and blood pressure [10]. It has been reported that CMKLR1 is 
expressed in vascular endothelial cells and that its expression 
level is regulated by inflammatory cytokines, such as tumor 
necrosis factor (TNF)-α, interleukin (IL)-1β, or IL-6 [11]. A 
very recent study also shows the role for chemerin/CMKLR1 
signaling in clonal expansion during adipocyte differentiation 
in bone marrow mesenchymal stem cells through the interac-
tion with peroxisome proliferator-activated receptor gamma 
(PPARγ), a master regulator of adipocyte differentiation [12]. 
These data show that chemerin is correlated with adipocyte 
differentiation, glucose metabolism, and inflammation, sug-
gesting its role in the pathophysiology of obesity, metabolic 
syndrome, and possibly type 2 diabetes mellitus. 
  Although accumulating data suggest a plausible role of 
chemerin in metabolic disorders, its role in atherosclerosis still 
remains elusive. Serum chemerin levels were reported to be 
weakly correlated with coronary plaque burden and the num-
ber of non-calcified plaques in humans, although the signifi-
cance disappeared after adjustment for the cardiovascular dis-
ease risk factors [9]. Another study demonstrated that aortic 
and coronary atherosclerosis assessed in 41 autopsy cases was 
positively correlated with chemerin expression in periaortic 
and pericoronary adipose tissue, suggesting the paracrine ef-
fects of chemerin on atherosclerosis [13]. Overexpression of 
chemerin in LDLRKO mice did not affect the atherosclerotic 
lesion area determined by en face analysis of the entire aorta 
[8]. The plausible mechanisms of the relationship between 
chemerin and development of atherosclerosis could be as fol-
lows: 1) the accumulation of chemerin in an atherosclerotic 
lesion could attract immune cells which contribute to the re-
modeling of the vessel wall, 2) the alteration of insulin sensi-
tivity and glucose uptake in adipocytes and skeletal muscle 
could contribute to development of atherosclerosis, and 3) 
chemerin could directly affect the inflammatory status in vas-
cular endothelial cells by increasing the production of nitric 
oxide via the activation of PI3K/Akt/eNOS pathways (Fig. 1) 
[14]. 
  In this issue, Hah et al. [15] reported that subjects with mul-
tiple stenotic coronary vessels showed higher serum chemerin 
levels than the subjects with only one stenotic coronary artery. 
However, when logistic regression analysis was performed with 
Fig. 1.  The proposed mechanism of the role of chemerin in atherosclerosis.
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conventional cardiovascular risk factors, such as C-reactive 
protein and low density lipoprotein cholesterol, chemerin was 
not an independent risk factor of multiple vessel disease. This 
study has implication in that it was the first study to assess ath-
erosclerosis directly by coronary angiogram, although the ab-
solute number of subjects was small. The disappearance of sig-
nificance of chemerin as the determinant of coronary artery 
stenosis after adjustment for cardiovascular risk factors sug-
gests that the influence of chemerin on the development of 
atherosclerosis might be explained more by the metabolic fac-
tors and the factors related with adipose tissues than the direct 
effects of chemerin on the initiation and progression of athero-
sclerotic plaque formation. However, there are other aspects 
involved in the development of atherosclerosis not yet studied 
in relation with chemerin expression, such as the effects of 
chemerin on vascular smooth muscle cell proliferation and 
migration, apoptosis, or plaque stability (Fig. 1). More study is 
needed to elucidate the role of chemerin in atherosclerosis and 
cardiovascular diseases.    
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